DETECT-ME study evaluates a non-endoscopic, methylation-based approach to identifying Barrett’s esophagus across 18 U.S. sites
Cyted Health:
| WHAT | Cyted Health will present clinical validation data from DETECT-ME, a prospective, 18-site U.S. study of the EndoSign® Barrett’s esophagus (BE) Test, as a late-breaking abstract in a plenary session at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting. Session: Plenary Session 4A: Esophagus / Practice Management Presentation #64: “A Prospective, Multicenter Cohort Study of a Novel Methylation Biomarker Panel Using Non-Endoscopic Cell Collection to Detect Barrett’s Esophagus – The DETECT-ME Study” (Late-Breaking Abstract) |
WHEN |
Wednesday, October 14, 2026, 10:00 – 10:10 AM CT |
WHERE |
ACG 2026 Annual Scientific Meeting, Music City Center, Nashville, Tennessee, Karl F. Dean Grand Ballroom A (Level 4) |
WHO |
Nicholas J. Shaheen, MD, MPH, MACG, University of North Carolina, Chapel Hill, NC, DETECT-ME study Principal Investigator Marcel Gehrung, CEO; Shirin R. Hasan VP, Medical & Clinical Affairs, available for interviews on site |
WHY |
Barrett’s esophagus, the only known precursor to esophageal adenocarcinoma, remains substantially underdiagnosed. The challenge is not confirming Barrett’s once a patient undergoes endoscopy; it is identifying and engaging at-risk patients early enough to get them to endoscopy in the first place. DETECT-ME compared Cyted’s non-endoscopic, methylation-based test directly against standard endoscopy and biopsy, using samples collected with the FDA 510(k)-cleared EndoSign® Cell Collection Device. The test is performed without sedation, with samples analyzed in Cyted’s CLIA-certified, CAP-accredited U.S. laboratory. The data will demonstrate how a scalable, non-endoscopic approach could provide a more accessible entry point into the diagnostic pathway, enabling more at-risk patients to reach endoscopy earlier in the course of disease. |
MEDIA |
Interviews with the investigators and Cyted Health leadership are available during ACG 2026. Full results will be released following the presentation. To schedule: Amba Swain, a.swain@cytedhealth.com |
About Cyted Health
Cyted Health believes early and accurate identification of esophageal disease can change the clinical clock - bringing clarity sooner, so clinicians can act earlier with greater impact.
The company is dedicated to improving early detection and prevention of esophageal adenocarcinoma. Its platform combines minimally invasive cell collection with high-resolution molecular analysis to detect early biological changes associated with Barrett’s esophagus and cancer. Cyted Health has built a robust portfolio of peer-reviewed publications and conducted over 40,000 tests using its diagnostic platform.
Cyted Health cares about restoring time when medicine does its best work: clearer answers, more informed decisions, and fewer patients left waiting in anxiety, so more people can get back to life, facing forward with confidence not concern.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261013729337/en/
Contacts
Steven Gottlieb
Steven.gottlieb@onestrat.com
